Sanofi's Amlitelimab Shows Significant Efficacy in Phase 3 Atopic Dermatitis Trial
Key Insights
Sanofi announced positive results from the global COAST 1 phase 3 trial evaluating amlitelimab in patients aged 12 and older with moderate-to-severe atopic dermatitis (search).
The fully human monoclonal antibody targeting OX40-ligand (search) demonstrated significant skin clearance and reduction in disease severity compared to placebo at week 24.
Amlitelimab showed efficacy when administered every 4 weeks or every 12 weeks, offering flexible dosing options for patients.
Sanofi has announced positive results from its global COAST 1 phase 3 trial evaluating amlitelimab, a fully human monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (search). The September 4, 2025 announcement marks a significant milestone for the novel therapeutic approach targeting OX40-ligand (search) in dermatological conditions.
Trial Design and Patient Population
The COAST 1 trial enrolled patients aged 12 years and older with moderate-to-severe atopic dermatitis (search). The study evaluated amlitelimab's efficacy when administered at two different dosing intervals: every 4 weeks and every 12 weeks, providing potential flexibility in treatment regimens.
Efficacy Results
At the primary endpoint of week 24, amlitelimab treatment demonstrated significant improvements in both skin clearance and reduction in disease severity compared to placebo. The positive results were observed across both dosing schedules, suggesting the antibody's sustained therapeutic effect even with extended dosing intervals.
Mechanism of Action
Amlitelimab represents a novel therapeutic approach as a fully human, non-T-cell depleting monoclonal antibody specifically directed against OX40-ligand (search). This mechanism distinguishes it from existing atopic dermatitis (search) treatments by targeting the OX40-ligand pathway, which plays a crucial role in inflammatory skin conditions.
Clinical Significance
The successful phase 3 results position amlitelimab as a potential new treatment option for patients with moderate-to-severe atopic dermatitis (search), particularly those aged 12 and older. The demonstrated efficacy with flexible dosing schedules could offer improved treatment convenience and patient compliance compared to more frequent dosing regimens required by some current therapies.
The positive COAST 1 data supports amlitelimab's progression toward potential regulatory submission, representing Sanofi's continued investment in innovative dermatological therapeutics targeting specific inflammatory pathways.